BriaCell(US:BCTX) Newsfilter·2025-04-23 11:30Core Insights - BriaCell Therapeutics Corp. is set to present four clinical data presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting its advancements in immunotherapy for cancer treatment [1][2]. Presentation Details - The first abstract titled "Update on phase III pivotal trial of Bria-IMT + CPI vs physician's choice in advanced metastatic breast cancer (BRIA-ABC)" will be presented on June 2, 2025, from 9:00 AM to 12:00 PM CDT, with the abstract number TPS1138 and poster board number 108a [2]. - The second abstract, "Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer," will also be presented on June 2, 2025, during the same time frame, with the abstract number 1096 and poster board number 75 [2]. - The third abstract, "Trial in progress: A study of Bria-OTS cellular immunotherapy in metastatic recurrent breast cancer," is scheduled for the same session, with the abstract number TPS1136 and poster board number 107a [2]. - A publish-only abstract titled "Impact of HLA Matching on Clinical Outcomes in a Phase 2 Trial of Bria-IMT™ Plus Anti PD1 in Advanced Breast Cancer" will be released on May 22, 2025, at 5:00 PM ET [2]. Company Overview - BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [4].